Dendreon (DNDN)

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. 

Dendreon’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates it has under development include investigational cellular immunotherapies targeted towards HER2/neu, carbonic anhydrase 9 (CA9) and carcinoembryonic antigen (CEA).


9/12: Aetna said it was expanding coverage to include Dendreon's Provenge cancer drug.

Address

Suite 3200, 1301 2nd Avenue
SEATTLE, WA 98101
United States

Website:  

http://www.dendreon.com